HOME >> BIOLOGY >> NEWS
Novel Two-Antibody Strategy To Fight Cancer Awarded Patent

Researchers at the University of Pennsylvania Medical Center today were awarded patent number 5,824,311 for a new technology that has shown the potential in laboratory studies to cure breast and other major cancers linked to certain abnormal genes.

Broadly viewed, the approach targets cancer-causing receptor molecules found on the surface of tumor cells with two different antibodies that bind to the molecules, fatally disabling the receptor's activity and leading to the cancer cell's death.

The specific application of the concept detailed in the patent employs a pair of antibodies against a receptor protein called p185. The p185 protein assembles into a two-protein receptor complex thought to be involved in stimulating the uncontrolled growth of a number of dangerous cancers, including those of the breast and the pancreas. Instructions for producing the p185 protein in the cell are encoded by a gene known as neu.

The recently approved anti-breast-cancer drug Herceptin also acts on the receptor produced by the neu gene but brings only one antibody to bear on it. Experiments in rodent models, however, showed that a two-antibody strategy was significantly more powerful.

"In our two-antibody studies, we were able to achieve cures of tumors as opposed to simply reducing tumor growth," says Mark I. Greene, MD, PhD, a professor of pathology and laboratory medicine in whose laboratory the work was conducted. "In our experience, a single antibody against the receptor only diminishes the growth of tumor cells, whereas two antibodies disable the receptor so effectively that the cells perish."

Receptor proteins are convoluted structures with many sites -- called epitopes -- to which a wide array of antibodies can bind. It is possible for some of these sites not to be involved in the activity of the protein. Also, antibodies that bind in different ways to the same site can limit each other's effectiveness. Signif
'"/>

Contact: Franklin Hoke
hokef@mail.med.upenn.edu
215-349-5659
University of Pennsylvania School of Medicine
20-Oct-1998


Page: 1 2

Related biology news :

1. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
2. Novel therapeutic bortezomib moves to phase II trial in lung cancer patients
3. Novel approaches to current cellular therapies continue progress toward disease prevention
4. Novel therapies show promise against myeloid leukemia
5. Novel sensors help clear the air
6. Fox Chase Cancer Center study: Novel DNA-repair gene mutation can cause resistance to cancer drugs
7. Novel proteins designed that block inflammation regulator associated with rheumatoid arthritis
8. Novel therapeutic target identified in fight against Rheumatoid Arthritis
9. Novel bacterium detoxifies chlorinated pollutants
10. Novel flu vaccine shows promise in mice
11. Novel gene therapy on the horizon, says Brenner Childrens Hospital pediatrician

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novel Two Antibody Strategy Fight Cancer Awarded Patent

(Date:7/23/2014)... Ind. Spinach gave Popeye super strength, but it ... a group of scientists: the ability to convert sunlight ... physicists are part of an international group using spinach ... by which plants convert the sun,s energy into carbohydrates ... study are part of the most efficient system ever ...
(Date:7/23/2014)... , , , ... , , , , ... lifespan. The idea, they argue, would be to target the... , , ... , , , , ... , , , , , , , Medicine focuses almost entirely on ...
(Date:7/23/2014)... its grip is affecting more than the color of people,s ... a heat-loving amoeba commonly found in warm freshwater bodies, such ... made warmer than usual this year. , A 9-year-old Kansas ... after swimming in several area lakes. The amoeba enters the ... the brain. Nose plugs can lower the odds of this ...
Breaking Biology News(10 mins):Spinach could lead to alternative energy more powerful than Popeye 2Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5Diseases of another kind 2
(Date:7/23/2014)... , July 23, 2014  Having the right people ... vital to accelerating business growth and achieving clinical and ... Association (AHA) Leadership Summit, July 20-22, 2014, in ... of hospital executives and healthcare experts discussing how partnerships ... Carrocino , President & Chief Executive Officer of Cape ...
(Date:7/23/2014)... StemGenex® , the leading resource for ... at improving the lives of patients dealing with degenerative ... disease. StemGenex believes that a commitment to the ... when providing care to patients with degenerative diseases. ... accessible to the millions of individuals currently living with ...
(Date:7/23/2014)... Iowa (PRWEB) July 23, 2014 DuPont ... the business as vice president of Agricultural Biotechnology (ABT), ... Biotechnology where he served most recently as president, chief ... biotechnology and business leadership in the seed and crop ... said Paul E. Schickler , president of DuPont ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 2DuPont Pioneer Names Neal Gutterson to Lead Agricultural Biotechnology 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7
Cached News: